Related Experiment Video
Updated: Aug 29, 2026

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense
Published on: April 17, 2026
Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp
1Servicio de Microbiología Clínica y E. Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain. ebouza@microb.net
Abstract:
Blastoschizomyces capitatus, Scedosporium prolificans and S. apiospermum are emerging fungal pathogens that may cause disseminated disease in neutropenic patients. They can present as fever resistant to antibiotics and to wide-spectrum antifungal agents, although they may involve almost every organ. The proportion of recovery from blood cultures is high and they are characteristically resistant to most antifungal agents. Prognosis is poor unless patients recover from neutropenia. Voriconazole has good in-vitro activity and is currently the drug of choice for these infections.
Insights
Emerging fungal pathogens like Blastoschizomyces capitatus and Scedosporium species cause severe infections in neutropenic patients. Voriconazole shows promising in-vitro activity and is the preferred treatment for these difficult-to-treat fungal infections.
Area of Science:
- Mycology
- Infectious Diseases
- Hematology
Background:
- Blastoschizomyces capitatus, Scedosporium prolificans, and S. apiospermum are increasingly recognized as significant fungal pathogens.
- These fungi can lead to disseminated infections, particularly in immunocompromised individuals such as neutropenic patients.
- Clinical presentation often includes persistent fever unresponsive to antibiotics and broad-spectrum antifungals, with potential multi-organ involvement.
Purpose of the Study:
- To highlight the clinical significance of Blastoschizomyces capitatus and Scedosporium species as emerging fungal pathogens.
- To discuss the challenges in treating infections caused by these fungi, including their resistance to conventional antifungal agents.
- To evaluate the role of voriconazole as a potential treatment option.
Main Methods:
- Review of clinical cases and in-vitro susceptibility data for Blastoschizomyces capitatus, Scedosporium prolificans, and S. apiospermum.
- Analysis of treatment outcomes in neutropenic patients with disseminated infections caused by these fungi.
- Assessment of voriconazole's in-vitro activity against these pathogens.
Main Results:
- These fungal pathogens are frequently isolated from blood cultures.
- Infections caused by these fungi are often characterized by resistance to multiple antifungal agents.
- Recovery from neutropenia is a critical factor for patient survival.
- Voriconazole demonstrates significant in-vitro activity against these emerging pathogens.
Conclusions:
- Blastoschizomyces capitatus and Scedosporium species pose a serious threat to neutropenic patients.
- Effective treatment is challenging due to antifungal resistance.
- Voriconazole is identified as a promising therapeutic agent for these infections, supported by its in-vitro efficacy.
Related Concept Videos
Cryptococcal Meningitis
Candidiasis
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Staphylococcal Skin Infections
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...